Rockwell Medical heads into its third-quarter report with its revenue decline finally in the rearview mirror, but with a harder question in front of it. Last quarter's 11% sales growth came as the company lapped the loss of DaVita volume, which made the comparison easier. This quarter has to show whether that growth reflects real momentum in the dialysis concentrate business, and whether the margin and cash gains management highlighted are enough to support a full-year profit target that still depends on a strong second half.

Analysts expect revenue of about $18.2 million, up 14.3% from $15.9 million a year ago and slightly ahead of the $17.8 million booked in the second quarter. The consensus loss of $0.13 per share compares with a $0.05 loss in the year-ago period, a 160% deterioration on paper. Per-share figures deserve caution, though, because the recently completed reverse stock split changes the share count. The underlying net loss has been narrowing, to $1.2 million last quarter from $1.6 million in the first quarter. Dollar losses and adjusted EBITDA will say more about the trend than EPS.

Management reaffirmed full-year sales guidance of $70 million to $75 million, and the Street's $72.45 million sits right at the midpoint. With first-half sales of $35.1 million, consensus implies about $37.4 million in the back half, so a quarter near $18.2 million would leave roughly $19 million needed in the fourth quarter. That is achievable but not trivial. The bigger stretch is profitability. Adjusted EBITDA was slightly negative in the second quarter against a full-year goal of $1 million to $2 million, so the third quarter should show EBITDA turning clearly positive. Another breakeven print would push most of the target into a single quarter, which would make reiterated guidance harder to believe.

The operating drivers management pointed to last quarter offer specific tests. Two automated liquid production lines, flagged earlier as lifting output by about half, are now running. That added capacity should show up in volume and in better gross margin as fixed costs are spread over more units. Gross margin reached 18%, the bottom of the 18% to 22% target, after 17% in the first quarter and 16% a year earlier. Movement toward 19% or 20% would confirm the operating leverage story, while slipping back would suggest the improvement came from mix rather than efficiency. The new Heritage Dialysis agreement, the renewed Aqua Dialysis contract, both with annual price escalators, and the recurring Western U.S. business at above-average margins should support both sales growth and pricing. Any update on the early-stage medical device project, which could make Rockwell only the second U.S. supplier of that product type, would also help, though it remains a longer-dated option.

Sentiment has improved sharply, from clearly bearish before the last report to modestly bullish now. The stock has slipped 1.3% since the prior release, but that beats a 5.4% drop in the S&P 500 by about four points. At $7.60, shares sit in the middle of their $6.68 to $8.90 post-earnings range and below the 200-day moving average near $8.21. That is a market that has started to give the turnaround some credit but has not yet committed to it.

The central issue is whether Rockwell can turn better volume and pricing into actual earnings. Revenue near or above $18 million with gross margin moving deeper into the target range and positive adjusted EBITDA would validate the improving narrative and make the full-year targets look credible. Growth driven mostly by easy comparisons, with margins stuck at 18% and EBITDA near zero, would leave the story resting on guidance rather than results.